LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Coherus Biosciences Inc

Chiusa

SettoreSettore sanitario

0.82 2.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.78

Massimo

0.83

Metriche Chiave

By Trading Economics

Entrata

-5.9M

-57M

Vendite

-47M

7.6M

P/E

Media del settore

1.741

51.198

EPS

-0.35

Margine di Profitto

-744.427

Dipendenti

221

EBITDA

115K

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+527.5% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-28M

90M

Apertura precedente

-1.68

Chiusura precedente

0.82

Notizie sul Sentiment di mercato

By Acuity

50%

50%

166 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 giu 2025, 14:31 UTC

Utili

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 19:36 UTC

Discorsi di Mercato

Oil Futures Post Solid Weekly Gains -- Market Talk

6 giu 2025, 19:28 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 giu 2025, 18:46 UTC

Discorsi di Mercato

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 giu 2025, 18:02 UTC

Discorsi di Mercato

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 giu 2025, 16:35 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:34 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:21 UTC

Discorsi di Mercato

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

6 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 giu 2025, 15:53 UTC

Discorsi di Mercato

Mexican Inflation Seen Rising in May -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 15:33 UTC

Discorsi di Mercato

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 giu 2025, 15:16 UTC

Discorsi di Mercato

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 giu 2025, 15:05 UTC

Discorsi di Mercato

Silver at its Highest In Nearly 15 Years -- Market Talk

6 giu 2025, 14:35 UTC

Discorsi di Mercato

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 giu 2025, 14:15 UTC

Discorsi di Mercato

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 giu 2025, 14:12 UTC

Utili

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 giu 2025, 14:09 UTC

Utili

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Confronto tra pari

Modifica del prezzo

Coherus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

527.5% in crescita

Previsioni per 12 mesi

Media 5.02 USD  527.5%

Alto 7 USD

Basso 1.05 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

4

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

166 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.